Engineered chimeric cytokines can generate gain-of-function activity in immune cells. Here, we report potent antitumor activity for a novel fusion cytokine generated by N-terminal coupling of GM-CSF to IL4, generating a fusokine termed GIFT4. B cells treated with GIFT4 clustered GM-CSF and IL4 receptors on the cell surface and displayed a pan-STAT hyperphosphorylation associated with acquisition of a distinct phenotype and function described to date. In C57BL/6J mice, administration of GIFT4 expanded endogenous B cells and suppressed the growth of B16F0 melanoma cells. Furthermore, B16F0 melanoma cells engineered to secrete GIFT4 were rejected immunologically in a B-cell-dependent manner. This effect was abolished when GIFT4-expressing B16F0 cells were implanted in B-cell-deficient mice, confirming a B-cell-dependent antitumor effect. Human GIFT4-licensed B cells primed cytotoxic T cells and specifically killed melanoma cells in vitro and in vivo. Taken together, our results demonstrated that GIFT4 could mediate expansion of B cells with potent antigen-specific effector function. GIFT4 may offer a novel immunotherapeutic tool and define a previously unrecognized potential for B cells in melanoma immunotherapy. Cancer Res; 74(15); 4133-44. Ó2014 AACR.
Introduction
Cytokine monotherapy for treatment of preestablished cancer has been characterized by modest clinical benefit (1) . This holds true for FDA-approved GM-CSF (2-4) and IL2 (5) . Nevertheless, cytokine-based cancer immunotherapy remains an active area of clinical research. Leukines such as IL7, IL15, and IL21 are now being studied in early-phase clinical trials (6) (7) (8) (9) (10) . An argument can be made that pharmacologic dosing of single-agent cytokine is unlikely to provide meaningful immune stimulus that will overcome the multiplicity of immune escape mechanisms deployed by prevalent tumor types (11) .
To address this potential limitation, we have developed the notion that physical coupling of functionally unrelated cytokines may display biochemical properties for which naturally evolved immune checkpoints deployed by tumors are lacking. As proof-of-concept, we have previously demonstrated that coupling of GM-CSF and common g-chain interleukins (aka GIFT fusokines) leads to novel biochemical properties (12, 13) . When compared with parental cytokines, GIFT fusokines initiate heretofore unheralded interleukin-receptor-driven STAT hyperactivation, which leads to enhanced immune antitumor activities via induction of tumor-killer NK cells by GIFT2 (derived from GM-CSF and IL2; refs. 14, 15) or tumoricidal dendritic cells by GIFT21 (from GM-CSF and IL21; refs. 16, 17) .
The notion of coupling GM-CSF to IL4 as a fusokine is appealing because it is known that their combined use can induce monocytes to differentiate into dendritic cells (18) . Indeed, many clinical dendritic cell-based cancer immunotherapy protocols utilize GM-CSF and IL4 as a means to generate autologous antigen-presenting cells (19) . Herein, we derived a novel fusokine: GIFT4 (derived from GM-CSF and IL4) and have discovered that GIFT4 promotes an entirely novel B-cell tumoricidal immune response characterized by both B helper and effector functions. This observation reveals the potential of both fusokine GIFT4 and GIFT4-licensed B cells (GIFT4-B cells) as meaningful tumoricidal agents.
Materials and Methods

GIFT4 gene and protein
GM-CSF and IL4 genes (cDNA; Invivogen) were cloned in frame allowing the expression of the chimeric transgenes and GIFT4 protein. The crystal structures of human GM-CSF and IL4 were used for homology modeling of GIFT4 three-dimensional structure on the software PROSPECT v2. GIFT4-encoding retroviral plasmid was introduced into authenticated GP2-293 packaging cells from Clontech. The retroparticles were used to genetically modify 293T and B16F0 cells from American Type Culture Collection (ATCC) authenticated by short tandem repeats (STR) analysis. GIFT4-expressing positive clones were selected by single cell culture in 96-well plates.
Similarly, B16F0 cells were genetically modified to stably expressing murine GM-CSF or IL4. Cytokine expression was confirmed by ELISA.
Cell culture
GIFT4-secreting 293T, B16F0, or nontransfected cells were cultured in DMEM medium. Culture supernatant was concentrated with sterile centrifugal filter units (Millipore Corporation). Splenic B cells from C57BL/6J (B6) mice were purified with pan B-cell enrichment kit (StemCell). Human B cells or T cells were purified from peripheral blood mononuclear cells (PBMC) of patients with melanoma with B-cell or T-cell enrichment kits (StemCell). B cells were cultured in complete RPMI-1640 medium in 96-well plate (10 5 cells/well) in presence of GIFT4, GM-CSF, and IL4 (2ng/mL; PeproTech) for 6 days. After wash with RPMI-1640 medium, B cells were cultured for 48 hours. The supernatants were then collected for luminex assay performed in the Human Immunology Monitoring Center at Stanford University (Stanford, CA). GIFT4-or control cytokine-treated human B cells were cocultured with autologous T cells (1:1) in RPMI-1640 medium for 6 days. Human A375 melanoma cells (2 Â 10 4 cells/well) from ATCC authenticated by STR analysis plus gender marker were cocultured with human T cells for 48 hours in a 96-well plate. After removal of T cells, melanoma cells were subject to MTT assay as described (20) .
ELISA and Western blot analysis
GIFT4, GM-CSF, IL4, and IFNg were quantified with ELISA kits (eBiosciences). GIFT4 was profiled by Western blot analysis (WB) with anti-GM-CSF or anti-IL4 antibodies (R&D Systems). Murine B cells (10 6 cells/mL) treated with GIFT4, GM-CSF, and IL4 with or without JAK inhibitors were lysed with buffer as described (21) . STAT phosphorylation in B cells was determined by Western blot analysis with anti-pSTAT1 (Tyr701, D4A7), anti-pSTAT3 (Tyr705, D3A7), anti-pSTAT5 (Tyr694, D47E7), anti-pSTAT6 (Tyr641, C11A12), or anti-STAT antibodies (Cell Signaling Technology). For immunoprecipitation of GMCSFRb by common gc receptor after GIFT4 or GM-CSF and IL4 stimulation, the B cells were lysed with buffer as described (21) . One mg of protein per sample was incubated with 2 mg of anti-common gc or anti-GMCSFR antibodies, or IgG isotype control (Santa Cruz Biotechnology) overnight at 4 C. The sample-antibody complexes were incubated with protein A agarose for 2 hours at 4 C. The bound proteins were eluted for Western blot analysis with anti-GMCSFR or anti-IL4R antibodies.
Confocal microscopy
B cells treated with GIFT4 or GM-CSF and IL4 (20 minutes at 37 C) were fixed with 3.7% paraformaldehyde, and stained with goat anti-mouse GMCSFRb (R&D Systems) and rabbit antimouse IL4R antibodies (Santa Cruz Biotechnology) overnight at 4
C. The cells were reacted with Donkey anti-rabbit Alexa 488 and Donkey anti-goat Alexa 555 (Invitrogen) at room temperature for 2 hours, and mounted with ProLong Gold Antifade Reagent with 4 0 ,6-diamidino-2-phenylindole (DAPI), and imaged under a Zeiss LSM 510 Confocal microscope.
Flow cytometry
GIFT4-treated splenocytes or B cells were profiled by flow cytometry (FACS) with antibodies against murine B220, CD3, CD19, CD22, CD23, CD25, CD27, CD40, CD69, CD80, CD83, CD86, MHCII, and IgM by FACS on a BD FACSCanto II flow cytometer. For GM-CSF staining, B cells were fixed and permeabilized with BD Cytofix/Cytoperm solution followed by anti-GM-CSF antibody staining. Human B cells were treated with human GIFT4, or GM-CSF and IL4 (20 ng/mL) for 6 days, and analyzed by FACS with a panel of antibodies against human B-cells. Cytotoxic T cells were profiled with anti-human CD3, CD8, CD314, INFg, granzyme B, and granulysin antibodies (BD). FACS data were analyzed with FlowJo 9.1 software.
Melanoma mouse model
B16F0, melan-a GNAQ Q209L cells [from Dr. Boris Bastian (coinventor) at University of California, San Francisco, authenticated by detecting a mutation in a Gnaq gene by PCR; San Francisco, CA], B16-GIFT4 cells, or B16-GMCSF/IL4 cells (10 6 /mouse) were subcutaneously implanted into syngeneic B6 mice or Rag1
On day 5, B6 mice pre-established with B16F0 or melan-a GNAQ Q209L melanoma tumors were intravenously administered with three doses of murine GIFT4 (100 ng/day/mouse) with 2-day interval. In addition, B16-GIFT4 cells were subcutaneously immunized into B6 mice for one month. Purified splenic B cells (10 Â 10 6 cells/mouse) from immunized mice were adoptively transferred into B16F0 tumor pre-established mMT mice (n ¼ 5 per group). B16-GIFT4 or B16F0 cells (10 6 cells/ mouse) in Matrigel solution (BD) were subcutaneously injected into B6 mice for 7 days. Tumors were harvested and digested as described (14) . Infiltrating lymphocytes were isolated with Lymphocyte Separation Medium (Mediatech). For examining the antimelanoma function of human GIFT4, human A375 melanoma cells (2 Â 10 5 cells/mouse) were subcutaneously implanted into NOD-scid IL2Rg null (NSG) mice. On day 5, human PBMC (10 Â 10 6 cells/mouse) were intravenously injected into the mice, supplemented with three doses of human GIFT4, GM-CSF and IL4 (100 ng/day/mouse), or PBS with 2-day interval. Alternatively, human B-cell primed T cells were intravenously injected into NSG mice with pre-established A375 melanoma. Tumor growth was measured with a digital caliper. All mice (6-8-week-old) were from Jackson Laboratory. The use of mice and the recruitment of patients with melanoma were approved by Emory University (Atlanta, GA).
Statistical analysis
Data were shown as mean AE SEM. P values were calculated using the ANOVA test or two-tailed Student t test in Supplementary Fig. S3D . P<0.05 was considered significant ( Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001).
Results
The effect of GIFT4 on murine B cells Murine GIFT4 has a single polypeptide chain of 282 amino acids (Fig. 1A) , with a predicted three-dimensional structure (Fig. 1B) . GIFT4 (50 kDa) produced by bioengineered 293T cells 
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GM-CSF IL4 67 kDa 49 kDa IL4 GM-CSF Figure 1 . Murine GIFT4 induced robust B-cell proliferation in vitro. A, murine GIFT4 protein sequence. B, predicted 3D structure of murine GIFT4. C, murine GM-CSF, IL4, or GIFT4 was blotted onto a nitrocellulose membrane and detected by Western blot with anti-GM-CSF or IL4 antibodies. D, splenic B cells from B6 mice were stimulated with GIFT4 or GM-CSF and IL4 or PBS for 6 days. Cells were photographed under a microscope (Â10). E, CFSE-labeled B cells were treated with GIFT4 (black), GM-CSF and IL4 (gray), or PBS (white) for 6 days, and subjected to FACS analysis. F, B-cell number increase was presented as fold-change based on initial number. G and H, the culture supernatants of murine B cells stimulated with GIFT4 (white), GM-CSF, and IL4 (gray) or PBS (black) were collected for cytokine luminex assay. Data were from three independent experiments. I, GIFT4-(black), GM-CSF and IL4-treated (gray) B cells were stained with antibodies against murine B-cell markers or with antibody isotype (white) and profiled by FACS. Data represent one of the three independent experiments.
was detected by Western blot analysis (Fig. 1C) . To test the effect of GIFT4 on resting leukocytes, splenocytes from na€ ve B6 mice were stimulated with murine GIFT4 or control cytokines. We observed that GIFT4 triggers the expansion of splenocytes ( Supplementary Fig. S1A ) predominantly in the B-cell compartment (Supplementary Fig. S1B and S1C). Working with purified splenic B cells, we confirmed that murine GIFT4 induced the robust proliferation of B cells ( Fig. 1D-F) . Luminex analysis on the culture supernatant of B cells showed that GIFT4-B cells produced significantly higher levels of cytokines IL1a, IL6, IL12 ( (Fig. 1I) . To test the effect of GIFT4 stimulation on Bcell STAT signaling, splenic B cells were stimulated with GIFT4 and compared with controls. We observed that GIFT4 on its own leads to hyperphosphorylation of STAT1, STAT3, STAT5, and STAT6 contemporaneously in B cells in a manner distinct to that observed with control cytokine treatment ( Fig. 2A) . To test whether JAKs are involved in GIFT4-induced STAT hyperphosphorylation, B cells were incubated with JAK inhibitors before GIFT4 stimulation. We observed that inhibition of JAK2 or JAK3 completely abrogated STAT1 phosphorylation; suppression of JAK1 or JAK3 robustly reduced the phosphorylation of STAT3, STAT5 and STAT6. Collective inhibition of JAKs completely interrupted STAT1, STAT3, STAT5, and STAT6 signaling ( Fig. 2A) . Consequently, blocking JAK1, JAK2, or JAK3 with its inhibitors dramatically suppressed GIFT4-induced Bcell proliferation (Fig. 2B ). To test ability of GIFT4 to cluster GMCSFR and IL4R on B-cell surface, coimmunoprecipitation was performed with anti-GMCSFR or anti-IL4R antibodies on the lysates from treated B cells. Indeed, GMCSFR was pulled down with IL4R after GIFT4 treatment (Fig. 2C ), but not after GM-CSF and IL4 stimulation. Confocal microscopy with anti-GMCSFR and anti-IL4R antibodies ( Fig. 2D and E) further confirmed the colocalization of GMCSFR and IL4R on GIFT4-treated B cells (Fig. 2E ), but not on control cytokine-treated cells (Fig. 2D) .
GIFT4 robustly expands endogenous B cells and promotes antitumor immunity B cells play important roles in host immunity against pathogens (22) and tumors (23, 24) . We therefore investigated whether the hypermorph effects of GIFT4 on B cells lead to an enhanced B-cell-driven immune response. To test the immune effect of murine GIFT4 in vivo, GIFT4 or GM-CSF and IL4 were intravenously administered into B6 mice. After one week, GIFT4-treated mice developed splenomegaly (Fig. 3A) in comparison with GM-CSF and IL4-or PBS-treated mice, with marked expansion of splenocytes (Fig. 3B ). Mice treated with GM-CSF and IL4 showed normal sized spleens as well as the number of splenocytes (Fig. 3A and B) . Profiling B220 þ cells and CD3 þ cells demonstrated that there was a 3-fold expansion of splenic B cells in GIFT4-treated mice (Fig. 3C) , and modest but significant expansion of T cells (Fig. 3C ) in comparison with GM-CSF and IL4-or PBS-treated groups. Intracellular staining further confirmed the induction of GM-CSF-secreting B cells by GIFT4 ( Supplementary Fig. S3C and S3D ), akin to the recently described innate response activator (IRA) B cells (22) . The percentage of GM-CSF þ B cells in GIFT4-treated mice is more than 30-fold higher when compared with GM-CSF and IL4-treated controls (Supplementary Fig. S3C and S3D) and the latter is similar to untreated mice. To test whether GIFT4 protein promotes a therapeutic antitumor response in vivo, we implanted B16F0 melanoma cells into B6 mice and 5 days later treated mice with GIFT4, GM-CSF and IL4, or PBS. We observed significant suppression of melanoma growth in GIFT4-treated mice (Fig. 3D) . As an independent validation of antimelanoma activity, we implanted B6 mice with syngeneic melan-a cells stably transduced with GNAQ Q209L as described (25) . In comparison with GM-CSG and IL4 or PBS treatments, GIFT4 significantly inhibited melan-a GNAQ Q209L tumor growth (Fig. 3E ).
GIFT4-triggered antitumor immunity is B-cell dependent
To further test the antitumor function of GIFT4, we generated genetically modified B16F0 melanoma cell lines stably expressing murine GIFT4, GM-CSF, or IL4 cytokine. The tumor cells were implanted into B6 mice. Twenty days later, mice implanted with wild-type B16F0 cells or with an admixture of B16F0-GMCSF and B16F0-IL4 cells developed melanoma tumors (Fig. 4A) . However, tumor growth was substantially inhibited in mice implanted with B16-GIFT4 cells, indicating that GIFT4 expression significantly suppressed melanoma tumor growth (Fig. 4A) . To analyze whether GIFT4 expression affects the infiltration/expansion of B or T lymphocytes in tumor microenvironment, B16-GIFT4 cells, B16-GMCSF þ IL4 cells, or B16F0 cells were embedded in Matrigel and implanted into B6 mice. One week later, Matrigel implants were surgically excised, enzymatically dissociated, and cellular content analyzed by FACS. Consistent with GIFT4-induced splenic B-cell expansion, GIFT4 expression by B16F0 cells resulted in the robust increase of B-cell and T-cell number in tumor microenvironment (Fig. 4B) . To further determine the role of B cells and T cells in GIFT4-triggered antimelanoma immunity, we implanted B16-GIFT4 cells in Rag1 À/À mice that lack functional B and T cells. We observed that B16-GIFT4 tumor grew quickly in Rag1 À/À mice (Fig. 4C) confirming the pivotal role of lymphoid cells in antitumor effect of GIFT4. To test the hypothesis that B cells play a pivotal role in GIFT4-triggered antitumor response, we implanted B16-GIFT4 cells into B-celldeficient mMT mice and observed a robust growth of
Anti-IL4R G I F T 4 + I g G G I F T 4 + a n t i-I L 2 R γ G I F T 4 + a n t i- melanoma tumors (Fig. 4C) . To further test whether GIFT4-B cells can serve as T-cell helpers and promote antitumor immunity, T cells were cocultured with GIFT4-B cells or control B cells. Quantification of IFNg secretion in the culture supernatant by ELISA showed that GIFT4-B cells markedly enhanced T-cell IFNg production ( Supplementary Fig. S4 ), whereas GM-CSF and IL4-treated B cells have little effect (Supplementary Fig. S4 ). Using knockout mice, we confirmed that mice deficient in IFNg, but not IL10, could not suppress melanoma growth (Fig. 4D) . To further define the relative contribution of T-cell subsets in GIFT4-driven antimelanoma response, we implanted B16-GIFT4 cells in CD4 or CD8 T-celldeficient mice (Fig. 4E ) and observed an absolute loss of melanoma tumoricidal activity. To investigate whether GIFT4-B cells from B16-GIFT4 cell-immunized mice could rescue antitumor immunity in B-cell-deficient mice, we performed adoptive transfer experiments. We implanted B16-GIFT4 cells into mMT mice and when mice developed palpable melanoma tumors, splenic B cells purified from immunized B6 mice were adoptively transferred. Measurement of tumor size showed that adoptive transfer of GIFT4-B cells from immunized mice significantly inhibited tumor growth in mMT mice (Fig. 4F ). We were unable to detect acquisition of anti-GIFT4 antibodies in serum of B16-GIFT4 cell-immunized mice as well as GIFT4-treated B6 mice ( Supplementary Fig. S5 ).
Human ortholog of GIFT4 induces B-effector immune response
To test whether human GIFT4 deploys similar B-cell stimulatory antimelanoma function as murine GIFT4, we cloned human GIFT4 cDNA and genetically modified 293T cells. Human GIFT4 protein sequence is showed in Fig. 5A , and intact protein expression was confirmed by Western blot analysis (Fig. 5B) . To examine the effect of human GIFT4 on B cells, we purified B cells from PBMC isolated from patients with melanoma (n ¼ 6). Treatment of B cells with human GIFT4 revealed that GIFT4 induced robust proliferation of peripheral B cells (Fig. 5C and D) . Phenotyping by FACS showed that human GIFT4-B cells are CD20
, and MHCII þ , with enhanced expression of CD27, CD40, and CD83; but are absent of CD23 and CD138 (Fig. 5E) . Profile of the secretome with luminex assay uncovered that human GIFT4-B cells from patients with melanoma produced substantial amount of IL2, IL6, CCL3, CCL4, ICAM1, and GM-CSF (Fig. 5F ).
Human GIFT4-B cells trigger melanoma-killing T-cell response
To test the translational property of human GIFT4-B cells as T-cell stimulators, we cocultured GIFT4-B cells, or GM-CSF and IL4-treated B ells with autologous carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled T cells isolated from melanoma patient's PBMC (n ¼ 8). Analysis of T-cell proliferation by FACS demonstrated that GIFT4-B cells, but not control B cells, promoted the proliferation of cocultured T cells (Fig. 6A) ; the majority of those cells were CD8 T cells (Fig.  6B) . To examine whether those T cells are cytotoxic cells, we performed surface and intracellular staining with anti-human
PBS GM-CSF GIFT4 + IL4 CD20   CD80  CD83  CD86  CD138  MHC I  MHC II   CD22  CD23  CD27  CD40   3,000 2,000 NKG2D (CD314), granzyme B, granulysin, and IFNg. FACS analysis showed that T cells primed by GIFT4-B cells mainly expressed tumor-killing NKG2D molecule (Fig. 6C) , and produced granzyme B, granulysin, and IFNg ( Fig. 6D and E) . 
with T cells (from patients with melanoma) primed by GIFT4-B cells (GIFT4 T cells) or T cells primed with GM-CSF and IL4-treated B cells (GMCSF/IL4 T cells).
We have observed that GIFT4 T cells killed the majority of melanoma cells within 48-hour coculture, without affecting the growth of HUVEC; in contrast, GMCSF/IL4 T cells had little killing effect on melanoma cells (Fig. 6F) . To test the hypothesis that human GIFT4 has similar antimelanoma effect in vivo as murine GIFT4, we implanted A375 cells into NSG mice. On day 5, ten millions of PBMC from patients with melanoma were delivered into the mice, supplemented with injection of human GIFT4, or GM-CSF and IL4. In comparison with GM-CSF and IL4 treatment or control group without PBMC, GIFT4 administration significantly reduced human melanoma growth in mice (Fig. 6G) . To test whether the GIFT4 T cells could kill human tumor cells in vivo, A375 melanoma cells were implanted into NSG mice, supplemented with an intravenous injection of GIFT4 T cells or GMCSF/IL4 T cells.
Monitoring human melanoma growth demonstrated that adoptive transfer of GIFT4 T cells could directly kill human melanoma cells in the mice (Fig. 6H) . However, the mice developed large human melanoma tumors on day 30 when delivered with GMCSF/IL4 T cells or without T cells (Fig 6H) . Using B cells and T cells from healthy donors, we found that GIFT4-licensed B cells and primed T cells have similar antimelanoma functions to the ones from patients with melanoma ( Supplementary Fig. S6A-S6F ).
Discussion
B cells are a population of heterogeneous lymphocytes where effector and suppressor subsets cohabitate (26, 27) . B cells can promote tumor growth (28) by inhibiting T-cell tumoricidal activities (29, 30) . Conversely, B cells can secrete antitumor cytokines (24) and facilitate T-cell antitumor function (31, 32) . Virtually all studies here cited examining B-cell effector function in antitumor immunity examined the biology of primeval B cells bereft of pharmacologic activation. Herein, lays the novelty of GIFT4 as a B-cell tropic immune stimulator. Distinct from IL4 and GM-CSF, GIFT4 fusokine deploys a gainof-function hyperphosphorylation of STATs through assembly of GMCSFR and IL4R on B-cell surface. The consequences of this pan STAT activation on B cells are protean, including a robust mitogenic response and phenotypic conversion to a unique B-effector phenotype characterized by expression of B220, CD19, CD40, CD80, CD83, CD86, and IgM, but not CD23. Furthermore, GIFT4-B cells generate a unique secretome distinct from other known B-effector phenotypes described in mice, including: IL1a, IL6, IL12, IL5, VEGF, GM-CSF, and CCL3. There is no report that STAT phosphorylation results in CCL3 secretion by normal B cells; however, BCR stimulation can activate leukemic B cells to produce CCL3 (33 (35) , and that produced by GIFT4-B cells may play a similar role. To our knowledge, it is the first report that activated normal B cells can produce chemokine CCL3. Therefore, GIFT4-B cells have a distinct cytokine-secreting profile that can enhance T-cell antitumor immunity. Interestingly, GIFT4 expands B cells including GM-CSFsecreting IRA-like B cells. GM-CSF has been shown to increase the proliferation of antigen-activated cytotoxic T cells (36) ; and CCL3 is critical for recruiting CCR5 þ T cells in antitumor immunity (37) , suggesting that GM-CSF and CCL3-producing GIFT4-B cells may provide a direct helper effect toward T-cell immunity against tumors. Because activated CD80 þ CD86 þ B cells are potent antigen-presenting cells that can generate autologous antigen-specific cytotoxic T cells against melanoma (38, 39), this feature may also be operative in GIFT4-B cells.
The sum of these features may provide a mechanistic rationale for B-cell-dependent antimelanoma-driven effect of GIFT4. Indeed, we can map out a cascade of interaction where GIFT4-B cells license T cells to markedly increase IFNg production, cytotoxic factors granzyme B and granulysin secretion, and NKG2D/CD314 expression. The human ortholog of GIFT4 behaves similarly to murine GIFT4 and functions as an immune stimulator to induce the proliferation of human peripheral B cells. Like murine GIFT4-B cells, human GIFT4-B cells bear the typical surface costimulatory markers such as CD80, CD86, MHC I, MHC II, and enhance autologous T-cell activation, proliferation, and IFNg production. In addition, both murine and human GIFT4-B cells secrete common cytokines and chemokines such as IL6, GM-CSF, and CCL3. However, human GIFT4-B cells have a unique secretome profile, producing substantial amount of T-cellsupportive cytokine IL2 and driving a CD8 T-cell response. B cells can enhance granzyme-B þ cytotoxic CD8 T-cell survival (40) , and tolerize CD8 T cells (39, 41) . We found that human GIFT4-B cells trigger an antitumor immune response by cytotoxic CD8 T cells derived from patients with melanoma. Those GIFT4-B cell primed T cells express tumor cytotoxic factors, and can directly kill human melanoma cells. The unique property of GIFT4-B cells and GIFT4-B cell primed autologous T cells from patients with melanoma provides a potential novel strategy for personalized cell immunotherapeutic against melanoma. In summary, our data demonstrate that GIFT4 fusokine deploys a unique STAT activation response in na€ ve B cells, which converts them to helpers of T-cell activity as well as tumoricidal effectors via their immune-stimulatory effects. These observations support the notion that chimeric cytokines such as the fusokine GIFT4 here described can lead to a hypermorph phenotype and function of B cells and pharmacologic utility in ailments amenable to an enhanced immune response.
